849
Participants
Start Date
August 27, 2003
Primary Completion Date
July 29, 2013
Study Completion Date
December 31, 2018
rituximab
Given IV
cisplatin
Given IV
cytarabine
Given IV
dexamethasone
Given IV
gemcitabine hydrochloride
Given IV
The Queen Elizabeth Hospital, Woodville
University of Pittsburgh Cancer Institute, Pittsburgh
University of Cincinnati, Barrett Cancer Centre, Cincinnati
Indiana University Medical Center, Indianapolis
Rush-Presbyterian-St. Luke's Medical Centre, Chicago
Hackensack University Medical Center, Hackensack
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
CancerCare Manitoba, Winnipeg
The Moncton Hospital, Moncton
Dr. H. Bliss Murphy Cancer Centre, St. John's
QEII Health Sciences Center, Halifax
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Cancer Centre of Southeastern Ontario at Kingston, Kingston
London Regional Cancer Program, London
Credit Valley Hospital, Mississauga
Thunder Bay Regional Health Science Centre, Thunder Bay
Odette Cancer Centre, Toronto
St. Michael's Hospital, Toronto
Univ. Health Network-Princess Margaret Hospital, Toronto
Hopital Charles LeMoyne, Greenfield Park
CHUM - Hopital Notre-Dame, Montreal
CHUQ-Pavillon Hotel-Dieu de Quebec, Québec
CHA-Hopital Du St-Sacrement, Québec
Centre hospitalier universitaire de Sherbrooke, Sherbrooke
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
Lead Sponsor
NCIC Clinical Trials Group
NETWORK